Advanced Gastric Cancer
Oncology·MeSH: Lung Neoplasms
Prevalence
10.0 / 100K
Incidence
6.1 / 100K/yr
3 drugs in development·1 company·3 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Datopotamab Deruxtecan | Merus N.V. (MRUS) |
Phase 2(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Advanced Gastric Cancer?
BioSniper tracks 3 drugs in development for Advanced Gastric Cancer across 1 company.
How many clinical trials target Advanced Gastric Cancer?
There are 3 clinical trials targeting Advanced Gastric Cancer tracked by BioSniper.
What is the prevalence of Advanced Gastric Cancer?
The estimated prevalence of Advanced Gastric Cancer is approximately 10.0 per 100,000 population.
Deep-dive into Advanced Gastric Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis